Genelux Corp（GNLX）資訊與事件GNLXGenelux Corp

Gorilla Technology Borrow Rate Increases to 47.07%

Latest data shows the largest indicative borrow rate increases among liquid option names include: Gorilla Technology Group Inc (GRRR) 47.07% +3.09, GRANITESHARES 2X LONG MU DAILY ETF (MULL) 23.48% +1.97, Astex Pharmaceuticals Inc (ASTX) 11.98% +1.60, GRANITESHARES 2X LONG AMD DAILY ETF (AMDL) 10.75% +1.02, Tidal Trust II (IRE) 22.43% +0.77, Defiance Daily Target 2X Long RGTI ETF (RGTX) 33.10% +0.45, Genelux Corp (GNLX) 3.34% +0.43, Aries I Acquisition Corp (RAM) 11.07% +0.36, Kraneshares Sse Star Market 50 Index ETF (KSTR) 2.95% +0.36, and Defiance Daily Target 2X Long RKLB ETF (RKLX) 20.06% +0.35.

Genelux Publishes Case Report from OLVI-VEC-202-SCLC Trial

Genelux announced the publication of a case report from the ongoing Phase 1b dose escalation portion of its Phase 1b/2 OLVI-VEC-202-SCLC trial. The report was published in Frontiers in Oncology, a peer-reviewed journal published by Frontiers Media S.A. This is an open-label trial evaluating a single intravenous cycle with multiple doses of Olvi-Vec administered in combination with platinum and etoposide chemotherapy in patients with platinum-relapsed or platinum-refractory small cell lung cancer after failing previous first-line treatment with platinum and etoposide chemotherapy. The trial is being conducted by the company's licensing partner, Newsoara HYK Biopharmaceuticals Co., in China. In this case report, a 58-year-old woman was previously treated for extensive stage SCLC with four cycles of frontline standard treatment with platinum and etoposide, followed by radiotherapy to the lung and prophylactic brain radiotherapy resulting in a 14.3-month progression-free survival and a duration of response of 13 months. After progressing from standard frontline therapy, the patient received a single course of systemically administered Olvi-Vec, which was well tolerated, and then was re-challenged with eight cycles of platinum and etoposide. The patient achieved a deep and durable partial objective response, a PFS of 16.7 months and a DOR of 14.3 months, exceeding those observed during her first-line platinum-based treatment. Moreover, the patient achieved a deeper tumor reduction after 4 cycles of platinum re-challenge as compared to after 4 cycles of first-line treatment, representing an absolute reduction of 22.0 mm versus 11.6 mm. This patient's experience exceeds historical outcomes reported with platinum rechallenge and support the hypothesis that Olvi-Vec-mediated changes in the tumor microenvironment may contribute to renewed sensitivity to platinum-based therapy.

Genelux Reports Significant Clinical Progress in Q2

"During the second quarter, the Company continued to make meaningful clinical and operational progress. We look forward to reporting the upcoming topline data of our Phase 3 OnPrime/GOG-3076 registrational trial, as well as dose-finding updates from our systemic administration studies in lung cancer," said Thomas Zindrick, President, CEO and Chairman of Genelux. "Recent translational findings further support Olvi-Vec's tumor-priming immunotherapy mechanism and its potential to promote tumor sensitization to platinum-based chemotherapy, as well as strengthening the scientific foundation of our ongoing clinical development programs."